It has been reported that RU486 induces G1-S blockage of the cell cycle in human ovarian cancer cells [50] and that RU486 reduces the activity of cdk2, enzyme that is involved in the regulation of the transcription factor E2F1 which modulates S-phase progression [51, 52]. This evidence concerns the gene E2F1 and ovarian cancer.